摘要
肝硬化是肝脏的一种弥漫性病理生理状态,被认为是各种肝损伤的最后阶段,特征为慢性炎症和纤维化,随后正常肝组织结构转换成结构异常结节、密集的纤维间隔,紧接着实质疲倦和肝脏组织的瓦解。由乙肝和(或)丙肝造成的酒精性肝病和慢性感染仍是世界范围肝硬化的主要症状。在漫长的15-30年期间,慢性肝疾病会导致肝硬化及其并发症。活性肝炎在炎症坏死再生中起着重要的作用,最终将导致肝硬化和原发性肝细胞癌。肝硬化的预后是高度可变的,受多个变量的影响,如病因、病情的严重程度、并发症和合并症的存在。在肝硬化晚期,生存率下降到1-2年。正确的先进性的诊断和不同小分子选择性治疗有助于理解肝纤维化的机制,这是肝硬化病理学驱动力,有助于用更严谨的方法来达到更有效的治疗方案。为防止肝功能进一步退化引起的纤维化常要求特异性治疗,即靶向治疗。因此,本文旨在评估以病理生理学为基础的肝硬化的诊断和治疗,用PubMed数据库搜寻从2011年至今的英文出版的相关文献。
关键词: 并发症;纤维症;肝硬化;肝脏;瞬间弹性成像
图形摘要
Current Drug Targets
Title:Recent Advancements in Diagnosis and Therapy of Liver Cirrhosis
Volume: 17 Issue: 15
Author(s): Roberto Giulio Romanelli, Cristina Stasi
Affiliation:
关键词: 并发症;纤维症;肝硬化;肝脏;瞬间弹性成像
摘要: Cirrhosis is a diffuse pathophysiological state of the liver considered to be the final stage of various liver injuries, characterized by chronic necroinflammatory and fibrogenetic processes, with subsequent conversion of normal liver architecture into structurally abnormal nodules, dense fibrotic septa, concomitant parenchymal exaustment and collapse of the liver tissue. Alcoholic liver disease and chronic infections due to HBV and/or HCV constitute the main causes of liver cirrhosis worldwide. During a lag time of 15 to 30 years, chronic liver diseases can lead to liver cirrhosis and its complications. Active hepatic inflammation plays a pivotal role in the inflammation- necrosis-regeneration process, which eventually leads to liver cirrhosis and hepatocellular carcinoma. Prognosis of liver cirrhosis is highly variable and influenced by several variables, such as etiology, severity of liver disease, presence of complications and comorbidities. In advanced cirrhosis, survival decreases to one or two years. Correct advanced diagnosis and selected treatment with different molecules may help in understanding mechanisms of fibrogenesis, the driving forces of cirrhosis’s pathogenesis, and the scrupulous approach to more effective therapeutic procedures. Prevention of fibrosis with further deterioration of liver function through specific treatments is always required, through the removal of the underlying causes of liver disease. Advanced liver disease, with subsequent complications, requires targeted treatment. Therefore, the aim of this review is to assess the diagnosis and treatment of liver cirrhosis on the pathophysiological bases, searching for relevant studies published in English using the PubMed database from 2011 to the present.
Export Options
About this article
Cite this article as:
Roberto Giulio Romanelli, Cristina Stasi , Recent Advancements in Diagnosis and Therapy of Liver Cirrhosis, Current Drug Targets 2016; 17 (15) . https://dx.doi.org/10.2174/1389450117666160613101413
DOI https://dx.doi.org/10.2174/1389450117666160613101413 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Related Journals
Related Books
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Ventilatory Abnormalities During Exercise in Heart Failure: A Mini Review
Current Respiratory Medicine Reviews Patterns of Self-Medication with Medicinal Plants and Related Adverse Events - A South American Survey
Current Drug Safety Diabetic Retinopathy and Atherosclerosis: is there a Link?
Current Diabetes Reviews Phenotypic Screening for Pharmaceuticals Using Tissue Constructs
Current Pharmaceutical Biotechnology Targeting ADAM12 in Human Disease: Head, Body or Tail?
Current Pharmaceutical Design The Involvement of Lysosomes in Myocardial Aging and Disease
Current Cardiology Reviews Use of Bromine-76 and Iodine-123 Radiohalogenated Tracers in the Drug Development Process
Current Pharmaceutical Design Impact of Angiotensin Converting Enzyme Inhibitors/Angiotensin Receptors Blockers on Mortality in Acute Heart Failure Patients with Left Ventricular Systolic Dysfunction in the Middle East: Observations from the Gulf Acute Heart Failure Registry (Gulf CARE)
Current Vascular Pharmacology Characterizing the Bi-Subunit Type IB DNA Topoisomerase of Leishmania Parasites; a Novel Scenario for Drug Intervention in Trypanosomatids
Current Drug Targets The Cardiac Antihypertrophic Effects of Cyclic GMP-Generating Agents: An Experimental Framework for Novel Treatments of Left Ventricular Remodeling
Vascular Disease Prevention (Discontinued) Induced Pluripotent Stem Cells in Regenerative Medicine and Disease Modeling
Current Stem Cell Research & Therapy The Delivery of Personalised, Precision Medicines <i>via</i> Synthetic Proteins
Drug Delivery Letters The Heart Metabolism: Pathophysiological Aspects in Ischaemia and Heart Failure
Current Pharmaceutical Design Mitochondrial Dysfunction and Endoplasmic Reticulum Stress in Diabetes
Current Pharmaceutical Design Approaches for Administering Chemotherapy in the Intensive Care Unit
Current Drug Safety The Role of Chymase in Vascular Remodeling and Tissue Fibrosis
Current Hypertension Reviews Inflammatory Syndrome in Chronic Kidney Disease: Pathogenesis and Influence on Outcomes
Inflammation & Allergy - Drug Targets (Discontinued) Levosimendan Preoperative
Current Pharmaceutical Design Nutritional and Pharmacological Management of Childhood Epilepsy: Ketogenic Diets and Common AEDs
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents SIRT1 as a Promising Novel Therapeutic Target for Myocardial Ischemia Reperfusion Injury and Cardiometabolic Disease
Current Drug Targets